effect of bimatoprost on alopecia areata

comparison of the effect of combined intralesional Triamcinolone with topical Bimatoprost versus intralesional Triamcinolone or topical Bimatoprost in the treatment of alopecia areata

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251014067632N1

Enrollment

Registered

2026-04-28

Start date

2026-02-03

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alopecia areata. Alopecia areata

Interventions

Intervention 1: Control group: was treated with intralesional triamcinolone injection (5mg/ml for scalp alopecia and 2.5mg/ml for facial alopecia) monthly for three months. Intervention 2: Interventio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ? People over 18 years of age with the hair loss pattern of alopecia areata who have at least one or more patches of alopecia. ? Consent to participate in the study.

Exclusion criteria

Exclusion criteria: ? Sensitivity to the medications used. ? Pregnancy and breastfeeding. ? Systemic treatment has been performed within the past 3 months or topical treatment has been performed within the past 2 weeks. ? The site of application of the medicine is infected. ? Patients with pattern universalis or ophiasis or totalis ? Patients with spontaneous hair regrowth in the area of ??hair loss ? Patients with other dermatological diseases simultaneously

Design outcomes

Primary

Measure	Time frame
Amount of change in the SALT score (from 0 to 100). Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: According to the areas involved in the scalp /left side:18% , right side=18%)/ ,top=40%,back=24 / (S0=no hair loss/ s1=<25% hair loss/ s2= 25%-49% hair loss/ s3=50%-74% hair loss/ s4=75-99%hairloss/ s5=100% total scalp hair loss).;Changes in dermoscopy findings. Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: Based on the researcher's observation (determining the number of black dots, yellow dots, broken hairs, exclamation mark hairs, villous hairs).;Checking the rate of change in GPA score. Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: Evaluation of patient outcomes by a physician outside the study based on the response rate to treatment using photographs taken before and one month after treatment (from 0 to 4) (A0 = no improvement / A1 = poor response <25% / A2 = good response 25 to 50% / A3 = very good response 50 to 75% / A4 = excellent response 75 to 100%).	—

Measure

Time frame

Amount of change in the SALT score (from 0 to 100). Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: According to the areas involved in the scalp /left side:18% , right side=18%)/ ,top=40%,back=24 / (S0=no hair loss/ s1=<25% hair loss/ s2= 25%-49% hair loss/ s3=50%-74% hair loss/ s4=75-99%hairloss/ s5=100% total scalp hair loss).;Changes in dermoscopy findings. Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: Based on the researcher's observation (determining the number of black dots, yellow dots, broken hairs, exclamation mark hairs, villous hairs).;Checking the rate of change in GPA score. Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: Evaluation of patient outcomes by a physician outside the study based on the response rate to treatment using photographs taken before and one month after treatment (from 0 to 4) (A0 = no improvement / A1 = poor response <25% / A2 = good response 25 to 50% / A3 = very good response 50 to 75% / A4 = excellent response 75 to 100%).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegin Soozangar

Ahvaz University of Medical Sciences

negin.sgr@gmail.com+98 61 3292 1837

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026